Li Min, Yang Ming-Hui, Liu Yi, Luo Xiao-Dong, Chen Jian-Zong, Shi Heng-Jun
Institute of Chinese Medicine, the General Hospital of the People's Liberation Army, Beijing, 100853, China,
Chin J Integr Med. 2015 Jan;21(1):17-21. doi: 10.1007/s11655-014-1760-3. Epub 2014 Jun 10.
To analyze the clinical evaluation of Parkinson's disease (PD) patients receiving integrated Chinese and Western medicine therapy.
One hundred and twenty patients were enrolled and randomly allocated to a control group or treatment group. Patients in the two groups received placebo and Bushen Huoxue Granule (, BHG), respectively. Both groups received baseline levodopa and benserazide (Madopar). The effects of treatment were assessed monthly during the 9-month treatment. Means of evaluation included Unified PD Rating Scale (UPDRS) scores (II and III), sleep scale score, 10 m turn back test (getting up time, 10 m×2 times, and turning time), timing motor test (TMT)-left and TMT-right, which were treated as the dependent variables; and age, sex, duration of PD, Hoehn and Yahr (H-Y) stage and Madopar dosage of admitted PD patients were as the independent variables. Multiple linear regression was used to analyze these factors.
H-Y stage significantly affected UPDRS II score, UPDRS III score, and getting up time (P<0.01). Madopar dosage and H-Y stage significantly affected the 10 m×2 times (P<0.05 or <0.01). Madopar dosage significantly affected the sleep scale score (P<0.05). There were also significant correlations between age and TMT-left or TMT-right (P<0.01), and duration of PD and TMT-right (P<0.05).
The six assessed means of clinical evaluation (including UPDRS II and UPDRS III scores, sleep scale score, getting up time, 10 m×2 times, and turning time) are sensitive indexes in all PD patients. H-Y stage and Madopar dosage are the major factors influencing means of clinical assessment of PD treatment.
分析帕金森病（PD）患者接受中西医结合治疗的临床评估情况。
纳入120例患者，随机分为对照组和治疗组。两组患者分别接受安慰剂和补肾活血颗粒（BHG）治疗。两组均接受基线左旋多巴和苄丝肼（美多芭）治疗。在9个月的治疗期间每月评估治疗效果。评估手段包括统一帕金森病评定量表（UPDRS）评分（II和III）、睡眠量表评分、10米折返试验（起床时间、10米×2次及转身时间）、定时运动试验（TMT）-左侧和TMT-右侧，将其作为因变量；而入院PD患者的年龄、性别、PD病程、Hoehn和Yahr（H-Y）分期及美多芭剂量作为自变量。采用多元线性回归分析这些因素。
H-Y分期显著影响UPDRS II评分、UPDRS III评分及起床时间（P<0.01）。美多芭剂量和H-Y分期显著影响10米×2次（P<0.05或<0.01）。美多芭剂量显著影响睡眠量表评分（P<0.05）。年龄与TMT-左侧或TMT-右侧之间也存在显著相关性（P<0.01），PD病程与TMT-右侧之间存在显著相关性（P<0.05）。
所评估的六项临床评估手段（包括UPDRS II和UPDRS III评分、睡眠量表评分、起床时间、10米×2次及转身时间）是所有PD患者的敏感指标。H-Y分期和美多芭剂量是影响PD治疗临床评估手段的主要因素。
